ScholarLens Back to search
2010•Chongqing Yike Daxue xuebaoRequires access

Experimental study of antiviral effects of recombinant eukaryotic plasmid PcDNA3.1-MxA on Hepatitis B virus

Qin Huang

Open publisher page 0 citations

Abstract

Objective:To investigate the anti-HBVeffects of the recombinant eukaryotic plasmid PcDNA3.1-MxAin HepG2.2.15 cells in vitro.Methods:The recombinant eukaryotic plasmid PcDNA3.1-MxA was transfected into HepG 2.2.15 cells with Lipofection after extracted and confirmed with restrictive endonuclease analysis.The control group was HepG2.2.15 cells transfected with PcDNA3.1.The levels of MxA mRNA were detected by RT-PCR and the titers of HBsAg and HBeAg in supernatant liquids were detected by ELISA.Results:The RT-PCR results showed the level of MxA mRNA in the treatment group was much higher than that in the control group.The titers ofHBsAgand HBeAgin supernatant liquid ofthe treatment group were significantlylower than those in the control group cells(P0.01).Conclusion:The study indicates that MxA protein can inhibit replication and expression of HBV.

About this research paper

What this paper is about

Objective:To investigate the anti-HBVeffects of the recombinant eukaryotic plasmid PcDNA3.1-MxAin HepG2.2.15 cells in vitro.Methods:The recombinant eukaryotic plasmid PcDNA3.1-MxA was transfected into HepG 2.2.15 cells with Lipofection after extracted and confirmed with restrictive endonuclease analysis.The control group was HepG2.2.15 cells transfected with PcDNA3.1.The levels of MxA mRNA were detected by RT-PCR and the titers of HBsAg and HBeAg in supernatant liquids were detected by ELISA.Results:The RT-PCR results showed the level of MxA mRNA in the treatment group was much higher than that in the control group.The titers ofHBsAgand HBeAgin supernatant liquid ofthe treatment group were significantlylower than those in the control group cells(P0.01).Conclusion:The study indicates that MxA protein can inhibit replication and expression of HBV.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate the anti-HBVeffects of the recombinant eukaryotic plasmid PcDNA3.1-MxAin HepG2.2.15 cells in vitro.Methods:The recombinant eukaryotic plasmid PcDNA3.1-MxA was transfected into HepG 2.2.15 cells with Lipofection after extracted and confirmed with restrictive endonuclease analysis.The control group was HepG2.2.15 cells transfected with PcDNA3.1.The levels of MxA mRNA were detected by RT-PCR and the titers of HBsAg and HBeAg in supernatant liquids were detected by ELISA.Results:The RT-PCR results showed the level of MxA mRNA in the treatment group was much higher than that in the control group.The titers ofHBsAgand HBeAgin supernatant liquid ofthe treatment group were significantlylower than those in the control group cells(P0.01).Conclusion:The study indicates that MxA protein can inhibit replication and expression of HBV.

Key concepts: Recombinant DNA, Transfection, Plasmid, HBsAg, HBeAg, Titer, Molecular biology, Virology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Experimental study of antiviral effects of recombinant eukaryotic plasmid PcDNA3.1-MxA on Hepatitis B virus — Research Paper | ScholarLens